|
Wednesday 8th November 2023 |
Text too small? |
In accordance with the Market Abuse Regulation the Company announces that it has today entered into a closed period, which will remain in place until the Company releases its half-yearly results for the period ended 30th September 2023.
The Company is satisfied that any inside information which the Directors or the Company may have during the closed period has previously been notified to a Regulated Information Service. The Company is therefore not prohibited from repurchasing its own securities, or issuing new securities, during this closed period.
For further information please e-mail temitcosec@franklintempleton.com or contact Client Dealer Services at Franklin Templeton on free phone 0800 305 306, +44 (0) 20 7073 8690 for overseas investors, or e-mail enquiries@franklintempleton.co.uk.
7th November 2023
END OF ANNOUNCEMENT
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
No comments yet
RYM - Ryman Healthcare appoints new independent director
ikeGPS 4Q FY26 and Full Year FY26 Performance Update
HGH - Heartland trading update
CVT - Comvita Rights Offer Opens
GNE - FY26 Q3 Performance Report and Updated Guidance
April 23rd Morning Report
Devon Funds Morning Note - 22 April 2026
AGL - Accordant Group Limited announces opening of Rights Offer
April 22nd Morning Report
BPG - Q4 FY26 Update: ARR reaches $26.8m